Treatment of hepatocellular carcinoma: a pivotal role for nuclear medicine?
- 1 February 2001
- journal article
- editorial
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 22 (2) , 119-120
- https://doi.org/10.1097/00006231-200102000-00001
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Intra-tumoural injection of 90Y microspheres into an animal model of hepatomaNuclear Medicine Communications, 2001
- Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy1Journal of the American College of Surgeons, 2000
- Long-Term Prognosis After Resection of Hepatocellular Carcinoma Associated With Hepatitis B–Related CirrhosisJournal of Clinical Oncology, 2000
- Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trialThe Lancet, 1999
- Imaging of metastases to the liverEuropean Radiology, 1996
- Superselective Intra-Arterial Radiometabolic Therapy With I-131 Lipiodol in Hepatocellular CarcinomaClinical Nuclear Medicine, 1996
- Epirubicin-lipiodol chemotherapy versus131iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinomaCancer, 1995
- Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II studyBritish Journal of Cancer, 1994
- Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres.Radiology, 1989
- Hepatic artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases.Radiology, 1988